Delay for Staar as FDA requests more implantable lens information
This article was originally published in Clinica
Staar Surgical is facing a further delay in its bid to gain FDA approval for its phakic implantable lens for correcting both astigmatism and myopia, a device that the firm believes to be an "integral part" of its strategy to develop its US refractive market.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.